Company / PP&E (Net)
TEVA PHARMACEUTICAL INDUSTRIES LTD PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$4.1B
FY2025
5-year range
$4.1B / $6.0B
FY2021-FY2025
Trend
-10.9%
vs FY2024
Sector context
#9 of 193
Health Care
What the data says
Among 193 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 5% for pp&e (net). Declined from $5.8B to $4.1B over the past 2 years.
Based on SEC 10-K filings.
$4.1B in FY2025 with a 5-year CAGR of -8.3%. Top quartile in the Health Care sector.
Declined from $5.8B to $4.1B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -10.8%
- 5-Year CAGR
- -8.3%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 193This company $4.1B Sector average $777.6M
▼
+424.7% above sector average
Key checks
Key Insights
- 5-year CAGR of -8.3%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 10.9% year-over-year.
- Ranks #9 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.1B | -10.9% |
| FY2024 | $4.6B | -20.3% |
| FY2023 | $5.8B | +0.2% |
| FY2022 | $5.7B | -4.1% |
| FY2021 | $6.0B | -5.0% |
| FY2020 | $6.3B | -2.2% |
| FY2019 | $6.4B | -6.3% |
| FY2018 | $6.9B | -10.5% |
| FY2017 | $7.7B | -5.0% |
| FY2016 | $8.1B | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026